HK1095761A1 - Compositions for treating neuropathic and neurodegenerative conditions - Google Patents
Compositions for treating neuropathic and neurodegenerative conditionsInfo
- Publication number
- HK1095761A1 HK1095761A1 HK07103355.6A HK07103355A HK1095761A1 HK 1095761 A1 HK1095761 A1 HK 1095761A1 HK 07103355 A HK07103355 A HK 07103355A HK 1095761 A1 HK1095761 A1 HK 1095761A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compositions
- neurodegenerative conditions
- treating neuropathic
- disclosed
- zinc finger
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 230000000626 neurodegenerative effect Effects 0.000 title 1
- 230000002981 neuropathic effect Effects 0.000 title 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 abstract 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 2
- 101710185494 Zinc finger protein Proteins 0.000 abstract 2
- 102100023597 Zinc finger protein 816 Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 230000000508 neurotrophic effect Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56056604P | 2004-04-08 | 2004-04-08 | |
| US63145504P | 2004-11-29 | 2004-11-29 | |
| PCT/US2005/011838 WO2005099771A2 (en) | 2004-04-08 | 2005-04-07 | Methods and compositions for treating neuropathic and neurodegenerative conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1095761A1 true HK1095761A1 (en) | 2007-05-18 |
Family
ID=34981912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK07103355.6A HK1095761A1 (en) | 2004-04-08 | 2007-03-29 | Compositions for treating neuropathic and neurodegenerative conditions |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20050267061A1 (xx) |
| EP (1) | EP1732614B1 (xx) |
| JP (1) | JP4903689B2 (xx) |
| AT (1) | ATE418346T1 (xx) |
| AU (2) | AU2005232665B2 (xx) |
| CA (1) | CA2561714A1 (xx) |
| DE (1) | DE602005011943D1 (xx) |
| ES (1) | ES2315859T3 (xx) |
| HK (1) | HK1095761A1 (xx) |
| WO (1) | WO2005099771A2 (xx) |
Families Citing this family (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007073513A2 (en) | 2005-11-10 | 2007-06-28 | Genvec, Inc. | Method for propagating adenoviral vectors encoding inhibitory gene products |
| AU2007212260A1 (en) * | 2006-02-09 | 2007-08-16 | Sangamo Therapeutics, Inc. | Method for treating peripheral arterial disease with zinc finger proteins |
| PT2415873E (pt) * | 2006-12-14 | 2015-03-31 | Sangamo Biosciences Inc | Proteínas com dedos de zinco não canónicas optimizadas |
| US8563314B2 (en) | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
| JP5702144B2 (ja) * | 2007-09-27 | 2015-04-15 | ダウ アグロサイエンシィズ エルエルシー | ５−エノールピルビルシキミ酸−３−リン酸シンターゼ遺伝子をターゲッティングする改変ジンクフィンガータンパク質 |
| EP2393506B1 (en) | 2009-02-04 | 2018-03-28 | Sangamo Therapeutics, Inc. | Methods and compositions for treating neuropathies |
| EP2461819A4 (en) * | 2009-07-28 | 2013-07-31 | Sangamo Biosciences Inc | METHODS AND COMPOSITIONS FOR TREATING TRI-NUCLEOTIDE REPEAT DISORDERS |
| US8518409B2 (en) * | 2010-05-31 | 2013-08-27 | Imperium Biotechnologies, Inc. | System for selective cell treatment using ideotypically modulated pharmacoeffectors |
| US8383405B2 (en) | 2010-05-31 | 2013-02-26 | Imperium Biotechnologies, Inc. | Methods of using ideotypically modulated pharmacoeffectors for selective cell treatment |
| JP6050230B2 (ja) | 2010-07-21 | 2016-12-21 | サンガモ バイオサイエンシーズ， インコーポレイテッド | Ｈｌａ遺伝子座の修飾のための方法及び組成物 |
| EP3511420B1 (en) | 2010-09-27 | 2021-04-07 | Sangamo Therapeutics, Inc. | Compositions for inhibiting viral entry into cells |
| ES2562421T3 (es) | 2010-10-12 | 2016-03-04 | The Children's Hospital Of Philadelphia | Métodos y composiciones para tratar la hemofilia B |
| WO2012094132A1 (en) | 2011-01-05 | 2012-07-12 | Sangamo Biosciences, Inc. | Methods and compositions for gene correction |
| RU2459630C1 (ru) * | 2011-04-27 | 2012-08-27 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Казанский (Приволжский) Федеральный Университет" (ФГАОУ ВПО КФУ) | Способ стимулирования нейрогенерации с помощью генетических конструкций |
| US9161995B2 (en) | 2011-07-25 | 2015-10-20 | Sangamo Biosciences, Inc. | Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene |
| CN108610423A (zh) | 2011-09-21 | 2018-10-02 | 桑格摩生物科学股份有限公司 | 调控转基因表达的方法和组合物 |
| CA3099582A1 (en) | 2011-10-27 | 2013-05-02 | Sangamo Biosciences, Inc. | Methods and compositions for modification of the hprt locus |
| JP6144691B2 (ja) | 2011-11-16 | 2017-06-07 | サンガモ セラピューティクス， インコーポレイテッド | 修飾されたｄｎａ結合タンパク質およびその使用 |
| AU2013225950B2 (en) | 2012-02-29 | 2018-02-15 | Sangamo Therapeutics, Inc. | Methods and compositions for treating huntington's disease |
| EP2847338B1 (en) | 2012-05-07 | 2018-09-19 | Sangamo Therapeutics, Inc. | Methods and compositions for nuclease-mediated targeted integration of transgenes |
| AU2013289206B2 (en) | 2012-07-11 | 2018-08-09 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of lysosomal storage diseases |
| CA2878037C (en) | 2012-07-11 | 2021-08-31 | Sangamo Biosciences, Inc. | Methods and compositions for delivery of biologics |
| US10648001B2 (en) | 2012-07-11 | 2020-05-12 | Sangamo Therapeutics, Inc. | Method of treating mucopolysaccharidosis type I or II |
| RS60838B1 (sr) | 2012-08-29 | 2020-10-30 | Sangamo Therapeutics Inc | Postupci i kompozicije za tretman genskog stanja |
| AU2013312538B2 (en) | 2012-09-07 | 2019-01-24 | Corteva Agriscience Llc | FAD3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
| UA119135C2 (uk) | 2012-09-07 | 2019-05-10 | ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі | Спосіб отримання трансгенної рослини |
| UA118090C2 (uk) | 2012-09-07 | 2018-11-26 | ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі | Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив |
| CA2886684C (en) | 2012-10-10 | 2023-09-19 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
| JP2016500254A (ja) | 2012-12-05 | 2016-01-12 | サンガモ バイオサイエンシーズ， インコーポレイテッド | 代謝疾患の調節のための方法および組成物 |
| WO2014130955A1 (en) | 2013-02-25 | 2014-08-28 | Sangamo Biosciences, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
| CA2942514A1 (en) * | 2013-03-15 | 2014-09-18 | University Of Florida Research Foundation | Compounds for treating neurodegenerative proteinopathies |
| EP3057432B1 (en) | 2013-10-17 | 2018-11-21 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells |
| CA2926094C (en) | 2013-10-17 | 2024-04-02 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| UA121459C2 (uk) | 2013-11-04 | 2020-06-10 | Дау Агросаєнсиз Елелсі | Рекомбінантна молекула нуклеїнової кислоти для трансформації рослини сої |
| KR102269769B1 (ko) | 2013-11-04 | 2021-06-28 | 코르테바 애그리사이언스 엘엘씨 | 최적 메이즈 유전자좌 |
| RU2719150C2 (ru) | 2013-11-04 | 2020-04-17 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Оптимальные локусы сои |
| NZ719494A (en) | 2013-11-04 | 2017-09-29 | Dow Agrosciences Llc | Optimal maize loci |
| JP2016537341A (ja) | 2013-11-11 | 2016-12-01 | サンガモ バイオサイエンシーズ， インコーポレイテッド | ハンチントン病を処置するための方法および組成物 |
| LT3068881T (lt) | 2013-11-13 | 2019-08-12 | Children`S Medical Center Corporation | Geno raiškos reguliavimas, tarpininkaujant nukleazei |
| DK3080274T3 (da) | 2013-12-09 | 2020-08-31 | Sangamo Therapeutics Inc | Fremgangsmåder og sammensætninger til genom-manipulation |
| DK3102673T3 (da) | 2014-02-03 | 2020-07-06 | Sangamo Therapeutics Inc | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi |
| JP6606088B2 (ja) | 2014-02-24 | 2019-11-13 | サンガモ セラピューティクス， インコーポレイテッド | ヌクレアーゼ媒介性標的化組み込みのための方法および組成物 |
| AU2015231353B2 (en) | 2014-03-18 | 2020-11-05 | Sangamo Therapeutics, Inc. | Methods and compositions for regulation of zinc finger protein expression |
| NZ728159A (en) | 2014-07-14 | 2018-08-31 | Univ Washington State | Nanos2 knock-out that ablates germline cells |
| CA2954414A1 (en) | 2014-07-15 | 2016-01-21 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| WO2016014837A1 (en) | 2014-07-25 | 2016-01-28 | Sangamo Biosciences, Inc. | Gene editing for hiv gene therapy |
| US9816074B2 (en) | 2014-07-25 | 2017-11-14 | Sangamo Therapeutics, Inc. | Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells |
| US9616090B2 (en) | 2014-07-30 | 2017-04-11 | Sangamo Biosciences, Inc. | Gene correction of SCID-related genes in hematopoietic stem and progenitor cells |
| JP6722176B2 (ja) | 2014-09-16 | 2020-07-15 | サンガモ セラピューティクス， インコーポレイテッド | 造血幹細胞におけるヌクレアーゼ媒介性ゲノム工学および補正のための方法および組成物 |
| RU2558294C1 (ru) | 2014-09-16 | 2015-07-27 | Общество с ограниченной ответственностью "НекстГен" | Кодон-оптимизированная рекомбинантная плазмида, способ стимуляции регенерации периферического нерва, способ лечения поврежденного нерва человека |
| US10889834B2 (en) | 2014-12-15 | 2021-01-12 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing targeted transgene integration |
| US20180002379A1 (en) | 2015-01-21 | 2018-01-04 | Sangamo Therapeutics, Inc. | Methods and compositions for identification of highly specific nucleases |
| CA2981077A1 (en) | 2015-04-03 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
| IL284707B2 (en) | 2015-05-12 | 2024-01-01 | Sangamo Therapeutics Inc | Regulation of nuclease-mediated gene expression |
| US9957501B2 (en) | 2015-06-18 | 2018-05-01 | Sangamo Therapeutics, Inc. | Nuclease-mediated regulation of gene expression |
| CN108024544B (zh) | 2015-07-13 | 2022-04-29 | 桑格摩生物治疗股份有限公司 | 用于核酸酶介导的基因组工程化的递送方法及组合物 |
| MA42895A (fr) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
| CN109475107A (zh) | 2015-08-06 | 2019-03-15 | 密苏里大学管理者 | 具有修饰的cd163基因的抗病原体动物 |
| AU2016369490C1 (en) | 2015-12-18 | 2021-12-23 | Sangamo Therapeutics, Inc. | Targeted disruption of the T cell receptor |
| AU2016374253B2 (en) | 2015-12-18 | 2021-10-21 | Sangamo Therapeutics, Inc. | Targeted disruption of the MHC cell receptor |
| CA3010738A1 (en) | 2016-01-15 | 2017-07-20 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of neurologic disease |
| EP3910059A1 (en) | 2016-05-27 | 2021-11-17 | Aadigen, Llc | Peptides and nanoparticles for intracellular delivery of genome-editing molecules |
| CN109863143B (zh) | 2016-07-13 | 2021-10-15 | 威泰克斯制药公司 | 提高基因组编辑效率的方法、组合物和试剂盒 |
| JP7203014B2 (ja) | 2016-08-24 | 2023-01-12 | サンガモ セラピューティクス， インコーポレイテッド | 工学操作されたヌクレアーゼを使用した遺伝子発現の調節 |
| CN110418841A (zh) | 2016-08-24 | 2019-11-05 | 桑格摩生物治疗股份有限公司 | 工程化的靶特异性核酸酶 |
| WO2018067826A1 (en) | 2016-10-05 | 2018-04-12 | Cellular Dynamics International, Inc. | Generating mature lineages from induced pluripotent stem cells with mecp2 disruption |
| MX2019004181A (es) | 2016-10-13 | 2019-10-30 | Juno Therapeutics Inc | Métodos y composiciones de inmunoterapia que implican moduladores de la ruta metabólica de triptófano. |
| WO2018075736A1 (en) | 2016-10-20 | 2018-04-26 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of fabry disease |
| CA3041668A1 (en) | 2016-10-31 | 2018-05-03 | Sangamo Therapeutics, Inc. | Gene correction of scid-related genes in hematopoietic stem and progenitor cells |
| AU2017367695A1 (en) | 2016-12-02 | 2019-06-13 | Juno Therapeutics, Inc. | Engineered B cells and related compositions and methods |
| JP7416406B2 (ja) | 2016-12-08 | 2024-01-17 | ケース ウェスタン リザーブ ユニバーシティ | 機能的ミエリン産生を増進させるための方法および組成物 |
| WO2018200943A1 (en) | 2017-04-28 | 2018-11-01 | Acuitas Therapeutics, Inc. | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| US11655275B2 (en) | 2017-05-03 | 2023-05-23 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene |
| US11512287B2 (en) | 2017-06-16 | 2022-11-29 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell and/or HLA receptors |
| EP3706766A4 (en) | 2017-11-09 | 2021-08-18 | Sangamo Therapeutics, Inc. | GENETIC MODIFICATION OF THE CYTOCINE INDUCTIBLE SH2-CONTAINING PROTEIN (CISH) GENE |
| JP2019103139A (ja) * | 2017-11-28 | 2019-06-24 | 芳樹 前澤 | コールセンター業務システム |
| AU2019209293B2 (en) | 2018-01-17 | 2023-07-27 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
| AU2019209290B2 (en) | 2018-01-17 | 2024-03-07 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
| ES2940786T3 (es) | 2018-01-17 | 2023-05-11 | Vertex Pharma | Compuestos de quinoxalinona, composiciones, métodos y kits para aumentar la eficiencia de edición del genoma |
| AU2019218118A1 (en) | 2018-02-08 | 2020-08-13 | Sangamo Therapeutics, Inc. | Engineered target specific nucleases |
| US11690921B2 (en) | 2018-05-18 | 2023-07-04 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
| WO2020041249A1 (en) | 2018-08-23 | 2020-02-27 | Sangamo Therapeutics, Inc. | Engineered target specific base editors |
| US20210348177A1 (en) | 2018-09-05 | 2021-11-11 | The Regents Of The University Of California | Generation of heritably gene-edited plants without tissue culture |
| CA3111711A1 (en) | 2018-09-18 | 2020-03-26 | Sangamo Therapeutics, Inc. | Programmed cell death 1 (pd1) specific nucleases |
| BR112021013654A2 (pt) | 2019-01-11 | 2021-09-14 | Acuitas Therapeutics, Inc. | Lipídeos para liberação de nanopartículas lipídicas de agentes ativos |
| CA3106693A1 (en) | 2019-02-06 | 2020-08-13 | Sangamo Therapeutics, Inc. | Method for the treatment of mucopolysaccharidosis type i |
| CN115141807A (zh) | 2019-04-02 | 2022-10-04 | 桑格摩生物治疗股份有限公司 | 治疗β-地中海贫血症的方法 |
| CA3136119A1 (en) | 2019-04-10 | 2020-10-15 | University Of Utah Research Foundation | Htra1 modulation for treatment of amd |
| WO2021022223A1 (en) | 2019-08-01 | 2021-02-04 | Sana Biotechnology, Inc. | Dux4 expressing cells and uses thereof |
| US20230025289A1 (en) | 2019-08-23 | 2023-01-26 | Sana Biotechnology, Inc. | Cd24 expressing cells and uses thereof |
| CN115279419A (zh) | 2019-11-01 | 2022-11-01 | 美商圣加莫治疗股份有限公司 | 用于基因组工程的组合物和方法 |
| TW202202155A (zh) | 2020-03-25 | 2022-01-16 | 美商薩那生物科技公司 | 用於治療神經病症及病況之低免疫原性神經細胞 |
| CN115803435A (zh) | 2020-05-06 | 2023-03-14 | 塞勒克提斯公司 | 用于在细胞基因组中靶向***外源序列的方法 |
| CN115715203A (zh) | 2020-05-06 | 2023-02-24 | 塞勒克提斯公司 | 对细胞进行基因修饰以递送治疗性蛋白质的方法 |
| US20230190871A1 (en) | 2020-05-20 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and compositions for treatment of viral infections |
| IL299787A (en) | 2020-07-16 | 2023-03-01 | Acuitas Therapeutics Inc | Cationic lipids for use in lipid nanoparticles |
| CA3188664A1 (en) | 2020-08-13 | 2022-02-17 | Sonja SCHREPFER | Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions |
| WO2022046760A2 (en) | 2020-08-25 | 2022-03-03 | Kite Pharma, Inc. | T cells with improved functionality |
| MX2023005665A (es) | 2020-11-16 | 2023-08-01 | Pig Improvement Co Uk Ltd | Animales resistentes a la influenza a que tienen genes de anp32 editados. |
| KR20230137900A (ko) | 2020-12-31 | 2023-10-05 | 사나 바이오테크놀로지, 인크. | Car-t 활성을 조정하기 위한 방법 및 조성물 |
| CA3216346A1 (en) | 2021-05-27 | 2022-12-01 | Edward Rebar | Hypoimmunogenic cells comprising engineered hla-e or hla-g |
| EP4370544A2 (en) | 2021-07-14 | 2024-05-22 | Sana Biotechnology, Inc. | Altered expression of y chromosome-linked antigens in hypoimmunogenic cells |
| EP4384193A2 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
| EP4384188A1 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Inducible systems for altering gene expression in hypoimmunogenic cells |
| EP4384544A1 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
| WO2023019227A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
| AU2022325232A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified primary cells for allogeneic cell therapy |
| AU2022343268A1 (en) | 2021-09-08 | 2024-03-28 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for modulating a genome |
| WO2023069790A1 (en) | 2021-10-22 | 2023-04-27 | Sana Biotechnology, Inc. | Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods |
| CA3237482A1 (en) | 2021-11-03 | 2023-05-11 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Precise genome editing using retrons |
| WO2023105244A1 (en) | 2021-12-10 | 2023-06-15 | Pig Improvement Company Uk Limited | Editing tmprss2/4 for disease resistance in livestock |
| AU2022422147A1 (en) | 2021-12-23 | 2024-07-04 | Sana Biotechnology, Inc. | Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods |
| WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| WO2023158836A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
| WO2023173123A1 (en) | 2022-03-11 | 2023-09-14 | Sana Biotechnology, Inc. | Genetically modified cells and compositions and uses thereof |
| WO2024013514A2 (en) | 2022-07-15 | 2024-01-18 | Pig Improvement Company Uk Limited | Gene edited livestock animals having coronavirus resistance |
| WO2024044723A1 (en) | 2022-08-25 | 2024-02-29 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| WO2024151541A1 (en) | 2023-01-09 | 2024-07-18 | Sana Biotechnology, Inc. | Type-1 diabetes autoimmune mouse |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) * | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4186183A (en) * | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4261975A (en) * | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US4485054A (en) * | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4603044A (en) * | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
| US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4897355A (en) * | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4946787A (en) * | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5049386A (en) * | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4797368A (en) * | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4774085A (en) * | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| US5422251A (en) * | 1986-11-26 | 1995-06-06 | Princeton University | Triple-stranded nucleic acids |
| US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US6001350A (en) * | 1987-12-11 | 1999-12-14 | Somatix Therapy Corp | Genetic modification of endothelial cells |
| US5674722A (en) * | 1987-12-11 | 1997-10-07 | Somatix Therapy Corporation | Genetic modification of endothelial cells |
| US5176996A (en) * | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US4957773A (en) * | 1989-02-13 | 1990-09-18 | Syracuse University | Deposition of boron-containing films from decaborane |
| US5693622A (en) * | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| US5698531A (en) * | 1989-03-31 | 1997-12-16 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5210015A (en) * | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| US5817491A (en) * | 1990-09-21 | 1998-10-06 | The Regents Of The University Of California | VSV G pseusdotyped retroviral vectors |
| US5849572A (en) * | 1990-10-10 | 1998-12-15 | Regents Of The University Of Michigan | HSV-1 vector containing a lat promoter |
| US5849571A (en) * | 1990-10-10 | 1998-12-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Latency active herpes virus promoters and their use |
| US5173414A (en) * | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5503022A (en) * | 1993-01-25 | 1996-04-02 | Barone; Larry A. | Marine impeller tester |
| US5797960A (en) * | 1993-02-22 | 1998-08-25 | Stevens; John H. | Method and apparatus for thoracoscopic intracardiac procedures |
| US5538848A (en) * | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| US6140466A (en) * | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| US5585245A (en) * | 1994-04-22 | 1996-12-17 | California Institute Of Technology | Ubiquitin-based split protein sensor |
| US6007988A (en) * | 1994-08-20 | 1999-12-28 | Medical Research Council | Binding proteins for recognition of DNA |
| US5789538A (en) * | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
| US5928939A (en) * | 1995-03-01 | 1999-07-27 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-b and dna coding therefor |
| US5797870A (en) * | 1995-06-07 | 1998-08-25 | Indiana University Foundation | Pericardial delivery of therapeutic and diagnostic agents |
| US5840059A (en) * | 1995-06-07 | 1998-11-24 | Cardiogenesis Corporation | Therapeutic and diagnostic agent delivery |
| US6344445B1 (en) * | 1995-10-19 | 2002-02-05 | Cantab Pharmaceutical Research Limited | Herpes virus vectors and their uses |
| EP0906069B1 (en) * | 1995-11-09 | 2004-02-04 | University of Massachusetts | Tissue re-surfacing with hydrogel-cell compositions |
| EP0871512A1 (en) * | 1995-12-22 | 1998-10-21 | Localmed, Inc. | Localized intravascular delivery of growth factors for promotion of angiogenesis |
| US6261552B1 (en) * | 1997-05-22 | 2001-07-17 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus vectors |
| US5928638A (en) * | 1996-06-17 | 1999-07-27 | Systemix, Inc. | Methods for gene transfer |
| GB9615794D0 (en) * | 1996-07-26 | 1996-09-04 | Medical Res Council | Mutant herpes simplex virus strains and uses thereof |
| US5976164A (en) * | 1996-09-13 | 1999-11-02 | Eclipse Surgical Technologies, Inc. | Method and apparatus for myocardial revascularization and/or biopsy of the heart |
| PT904392E (pt) * | 1996-10-17 | 2001-06-29 | Oxford Biomedica Ltd | Vectores retrovirais |
| US5931810A (en) * | 1996-12-05 | 1999-08-03 | Comedicus Incorporated | Method for accessing the pericardial space |
| US6067988A (en) * | 1996-12-26 | 2000-05-30 | Eclipse Surgical Technologies, Inc. | Method for creation of drug delivery and/or stimulation pockets in myocardium |
| US5999678A (en) * | 1996-12-27 | 1999-12-07 | Eclipse Surgical Technologies, Inc. | Laser delivery means adapted for drug delivery |
| US5925012A (en) * | 1996-12-27 | 1999-07-20 | Eclipse Surgical Technologies, Inc. | Laser assisted drug delivery |
| US20030219409A1 (en) * | 1997-01-10 | 2003-11-27 | Biovex Limited | Eukaryotic gene expression cassette and uses thereof |
| US5993443A (en) * | 1997-02-03 | 1999-11-30 | Eclipse Surgical Technologies, Inc. | Revascularization with heartbeat verification |
| US6045565A (en) * | 1997-11-04 | 2000-04-04 | Scimed Life Systems, Inc. | Percutaneous myocardial revascularization growth factor mediums and method |
| US5893839A (en) * | 1997-03-13 | 1999-04-13 | Advanced Research And Technology Institute, Inc. | Timed-release localized drug delivery by percutaneous administration |
| US6086582A (en) * | 1997-03-13 | 2000-07-11 | Altman; Peter A. | Cardiac drug delivery system |
| US5968010A (en) * | 1997-04-30 | 1999-10-19 | Beth Israel Deaconess Medical Center, Inc. | Method for transvenously accessing the pericardial space via the right atrium |
| GB9710809D0 (en) * | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| US5863736A (en) * | 1997-05-23 | 1999-01-26 | Becton, Dickinson And Company | Method, apparatus and computer program products for determining quantities of nucleic acid sequences in samples |
| US6007408A (en) * | 1997-08-21 | 1999-12-28 | Micron Technology, Inc. | Method and apparatus for endpointing mechanical and chemical-mechanical polishing of substrates |
| US5972013A (en) * | 1997-09-19 | 1999-10-26 | Comedicus Incorporated | Direct pericardial access device with deflecting mechanism and method |
| US6050986A (en) * | 1997-12-01 | 2000-04-18 | Scimed Life Systems, Inc. | Catheter system for the delivery of a low volume liquid bolus |
| US5994136A (en) * | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| GB9801930D0 (en) * | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
| US5997509A (en) * | 1998-03-06 | 1999-12-07 | Cornell Research Foundation, Inc. | Minimally invasive gene therapy delivery device and method |
| US6066123A (en) * | 1998-04-09 | 2000-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of bioavailability by use of focused energy delivery to a target tissue |
| US20040063094A1 (en) * | 1998-05-20 | 2004-04-01 | Biovex Limited | Mutant herpes simplex viruses and uses thereof |
| US6048332A (en) * | 1998-10-09 | 2000-04-11 | Ave Connaught | Dimpled porous infusion balloon |
| US6140081A (en) * | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| US6534261B1 (en) * | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6453242B1 (en) * | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US7030215B2 (en) * | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
| GB9930419D0 (en) * | 1999-12-22 | 2000-02-16 | Neurovex Ltd | Replication incompetent herpes virus vectors |
| GB9930418D0 (en) * | 1999-12-22 | 2000-02-16 | Neurovex Ltd | Replication incompetent herpes virus vectors |
| EP1568779A1 (en) * | 2000-01-21 | 2005-08-31 | BioVex Limited | HSV strains for the oncolytic treatment of cancer |
| GB0001476D0 (en) * | 2000-01-21 | 2000-03-15 | Neurovex Ltd | Herpes virus strains |
| US20020061512A1 (en) * | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
| US20020064802A1 (en) * | 2000-04-28 | 2002-05-30 | Eva Raschke | Methods for binding an exogenous molecule to cellular chromatin |
| CA2431308C (en) * | 2000-12-07 | 2010-04-13 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
| US7067317B2 (en) * | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
| ES2409080T3 (es) * | 2001-01-22 | 2013-06-24 | Sangamo Biosciences Inc. | Proteínas de unión con dedos de zinc modificadas |
| EP1570058A1 (en) * | 2002-12-09 | 2005-09-07 | Toolgen, Inc. | Regulatory zinc finger proteins |
-
2005
- 2005-04-07 WO PCT/US2005/011838 patent/WO2005099771A2/en not_active Application Discontinuation
- 2005-04-07 ES ES05732726T patent/ES2315859T3/es active Active
- 2005-04-07 AU AU2005232665A patent/AU2005232665B2/en not_active Ceased
- 2005-04-07 US US11/101,287 patent/US20050267061A1/en not_active Abandoned
- 2005-04-07 EP EP05732726A patent/EP1732614B1/en not_active Not-in-force
- 2005-04-07 CA CA002561714A patent/CA2561714A1/en not_active Abandoned
- 2005-04-07 DE DE602005011943T patent/DE602005011943D1/de active Active
- 2005-04-07 JP JP2007507511A patent/JP4903689B2/ja not_active Expired - Fee Related
- 2005-04-07 AT AT05732726T patent/ATE418346T1/de not_active IP Right Cessation
-
2007
- 2007-03-29 HK HK07103355.6A patent/HK1095761A1/xx not_active IP Right Cessation
-
2009
- 2009-10-08 US US12/587,517 patent/US20100256221A1/en not_active Abandoned
-
2010
- 2010-08-12 AU AU2010212293A patent/AU2010212293B2/en not_active Ceased
-
2011
- 2011-01-03 US US12/930,320 patent/US20110281937A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005232665A1 (en) | 2005-10-27 |
| JP2007532567A (ja) | 2007-11-15 |
| CA2561714A1 (en) | 2005-10-27 |
| AU2010212293A1 (en) | 2010-09-02 |
| US20050267061A1 (en) | 2005-12-01 |
| WO2005099771A3 (en) | 2005-12-08 |
| US20100256221A1 (en) | 2010-10-07 |
| DE602005011943D1 (de) | 2009-02-05 |
| WO2005099771A2 (en) | 2005-10-27 |
| EP1732614B1 (en) | 2008-12-24 |
| AU2005232665B2 (en) | 2010-05-13 |
| ES2315859T3 (es) | 2009-04-01 |
| US20110281937A1 (en) | 2011-11-17 |
| AU2010212293B2 (en) | 2012-07-19 |
| EP1732614A2 (en) | 2006-12-20 |
| ATE418346T1 (de) | 2009-01-15 |
| JP4903689B2 (ja) | 2012-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1095761A1 (en) | Compositions for treating neuropathic and neurodegenerative conditions | |
| WO2006034455A3 (en) | Polipeptide compounds for inhibiting angiogenesis and tumor growth | |
| AU2003293035A1 (en) | Treatment of neurodegenerative disease through intracranial delivery of short interfering rna (sirna) | |
| EP2345718A3 (en) | Compositions and methods for siRNA inhibition of angiogenesis | |
| WO2009045370A3 (en) | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof | |
| DE602004028587D1 (de) | ZUSAMMENSETZUNGEN UND VERFAHREN ZUR siRNA-HEMMUNG VON ICAM-1 | |
| WO2011020120A3 (en) | Multi-transgenic pigs for diabetes treatment | |
| EP1990059A3 (en) | methods for treating cancer | |
| WO2007140312A3 (en) | Anti-cross-linking agents and methods for inhibiting cross-linking of injectable hydrogel formulations | |
| WO2007022470A3 (en) | Methods and compositions for treating neurological disease | |
| ATE473630T1 (de) | Verfahren zur bekämpfung von pflanzenkrankheitsschäden durch verwendung eines bacillus | |
| UA104605C2 (xx) | Аналоги глюкагону$аналоги глюкагона | |
| UA104626C2 (ru) | Анти-vegf антитело и его применение | |
| SG170819A1 (en) | Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith | |
| WO2011090741A3 (en) | TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63 | |
| WO2004080425A3 (en) | Polypeptide compounds for inhibiting angiogenesis and tumor growth | |
| WO2010059004A3 (ko) | 스네일-p53 간의 결합을 저해하는 화합물 및 이를 유효성분으로 함유하는 암질환 치료제 | |
| EA201270574A1 (ru) | Способы и системы для фармакогеномного лечения сердечно-сосудистых заболеваний | |
| PT1901773E (pt) | Utilização da proteinase ides (de s. pyogenes) para o tratamento de doenças e rejeição de enxertos | |
| GEP20135853B (en) | Method of myelination and oligodendrocyte differentiation promotion | |
| WO2008008772A3 (en) | Methods for treating and limiting fibrotic disorders and keloids | |
| MX2021014460A (es) | Composiciones y metodos para la regulacion genica selectiva. | |
| EP4079750A3 (en) | Adenoviruses and methods for using adenoviruses | |
| WO2011066082A3 (en) | Markers associated with ribavirin-induced anemia | |
| WO2008059041A3 (en) | Complementation of factor xi deficiency by factor v mutants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20130407 |